Tue, Jan 27, 2015, 1:39 AM EST - U.S. Markets open in 7 hrs 51 mins

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • censored53 censored53 Jul 30, 2013 12:18 PM Flag

    Yasser's having a sissy fit, the con mans in a tizzy….

     

    “In a clinical study, 28% of patients on Juxtapid had diarrhea, nausea, vomiting, and abdominal pain. However, those side effects are minimal compared to those caused by traditional statin treatments. Liver tests are also required for patients before and after treatments, since Juxtapid can cause liver problems, according to the FDA. Therefore, patients considering using Juxtapid are required to first enroll in a Juxtapid REMS (Risk Evaluation and Mitigation Strategy) program for liver testing.

    A very high-priced treatment

    Investors are waiting to see if Juxtapid can break out of its niche and become a mainstream high LDL treatment, but that kind of approval could be years away. For now, Aegerion can only treat its small group of patients suffering from homozygous familial hypercholesterolemia, which only affects one in a million people. Due to the rarity of the disease, a year’s supply of Juxtapid costs $295,000 -- recently increased from $235,000.”

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ROFL - you crack me up crackpot. Patient count is up 186% - let me say that again - up 186% - quarter over quarter. That's huge. I thought you said nobody could afford it?

      See, there is this new thing, it's called INSURANCE.
      Never mind, you are too stupid to know, and too dumb to learn.

 
AEGR
24.94+0.07(+0.28%)Jan 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.